Literature DB >> 25398582

Successful treatment of metastatic rhabdomyosarcoma with radiochemotherapy and allogeneic hematopoietic stem cell transplantation.

Fumito Yamazaki1, Tomoo Osumi1, Naoyuki Shigematsu2, Hideo Morioka3, Hiroyuki Shimada4.   

Abstract

We report a case of a 21-year-old man with alveolar rhabdomyosarcoma primarily in the right hand with lymph node, lung, bone and bone marrow metastases. Complete remission was achieved after intensive chemotherapy and radiotherapy of the primary and metastatic sites, followed by allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning from a single HLA-DR locus-mismatched mother. The patient remained relapse-free for 41 months after the diagnosis. Considering that the conventional treatment for rhabdomyosarcoma with multiple risk factors (old age, bone or bone marrow involvement, unfavorable primary sites and ≥ 3 metastases) is associated with a poor prognosis (5% probability of a 3-year event-free survival), the graft-versus-tumor effect may have contributed to his sustained relapse-free survival. Allogeneic hematopoietic stem cell transplantation for rhabdomyosarcoma should be done by experienced clinical oncologists on properly designed controlled trials.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  chemotherapy; rhabdomyosarcoma; stem cell transplantation

Mesh:

Year:  2014        PMID: 25398582     DOI: 10.1093/jjco/hyu189

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

Review 1.  Head and neck rhabdomyosarcoma: follow-up results of four cases and review of the literature.

Authors:  Dong-Ni Zhou; Qing-Qing Yang; Zhong-Lin Li; Zhi-Yong Pan; Yan-Fei Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

Authors:  Sebastian Johannes Schober; Erika Hallmen; Florian Reßle; Hendrik Gassmann; Carolin Prexler; Angela Wawer; Irene von Luettichau; Ruth Ladenstein; Bernarda Kazanowska; Gustaf Ljungman; Felix Niggli; Olli Lohi; Julia Hauer; Bernd Gruhn; Thomas Klingebiel; Peter Bader; Stefan Burdach; Peter Lang; Monika Sparber-Sauer; Ewa Koscielniak; Uwe Thiel
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

3.  A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Authors:  Juliane Wagner; Viktoria Pfannenstiel; Anja Waldmann; Judith W J Bergs; Boris Brill; Sabine Huenecke; Thomas Klingebiel; Franz Rödel; Christian J Buchholz; Winfried S Wels; Peter Bader; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-06-12       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.